Related Experiment Video
Updated: Oct 24, 2025
03:47
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
944
Using a Global Systematic Framework Tool to Identify Pharmacy Workforce Development Needs: A National Case Study on
Dalia Almaghaslah1, Abdulrhman Alsayari2
1Department of Clinical Pharmacy, King Khalid University, Abha, Saudi Arabia.
Risk Management and Healthcare Policy
|August 16, 2021
Summary
Saudi Arabia’s pharmacy workforce development identified professional development as a priority. Key areas for improvement include competency, leadership, and collaboration, alongside continuing professional development strategies and impact measurement.
Area of Science:
- Pharmaceutical workforce development
- Healthcare systems analysis
- Saudi Vision 2030
Background:
- Saudi Vision 2030 emphasizes healthcare development.
- Assessing pharmacy workforce strengths and weaknesses is crucial for national health goals.
- Pharmacy workforce development is integral to achieving Saudi Vision 2030 objectives.
Purpose of the Study:
- To identify pharmacy workforce development needs in Saudi Arabia.
- To utilize the International Pharmaceutical Federation Development Goals (FIP DGs) as a framework.
- To guide strategic improvements in the Saudi pharmacy sector.
Main Methods:
- Employed a systematic framework using the International Pharmaceutical Federation Development Goals (FIP DGs).
- Analyzed the current state of pharmacy education and practice in Saudi Arabia.
- Identified priority areas for workforce enhancement based on the FIP DGs.
Main Results:
- Increased number of qualified Saudi pharmacy employees and educational institutions.
- Established postgraduate pharmacy programs and expanded clinical pharmacy residencies.
- Offered accredited continuing professional development (CPD) programs, though not always needs-based.
Conclusions:
- Professional Development (Cluster 2) is a priority area, specifically competency (DG 5), leadership (DG 6), and working with others (DG 8).
- Systems (Cluster 3) priorities include continuing professional development strategies (DG 9) and impact/outcome measurement (DG 11).
- Targeted improvements in professional development and system strategies are recommended for the Saudi pharmacy workforce.
Related Concept Videos
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
35
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
35
01:12Analysis of Population Pharmacokinetic Data
473
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
473
01:28International Nursing Organizations II
1.1K
The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
1.1K
01:28Structure-Activity Relationships and Drug Design
1.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.2K
01:28Dosage Regimens: Designs and Approaches
62
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
62
01:15Drug Dosing: Geriatric Patients
46
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
46